TNSN06200A1 - Derives de quinoleine nouveaux - Google Patents

Derives de quinoleine nouveaux

Info

Publication number
TNSN06200A1
TNSN06200A1 TNP2006000200A TNSN06200A TNSN06200A1 TN SN06200 A1 TNSN06200 A1 TN SN06200A1 TN P2006000200 A TNP2006000200 A TN P2006000200A TN SN06200 A TNSN06200 A TN SN06200A TN SN06200 A1 TNSN06200 A1 TN SN06200A1
Authority
TN
Tunisia
Prior art keywords
formule
composés
des
par
invention concerne
Prior art date
Application number
TNP2006000200A
Other languages
English (en)
Inventor
Robert Steven Kania
Yufeng Hong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738830&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN06200A1 publication Critical patent/TNSN06200A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés représentés par la formule (I), Et les sels ou produits de solvatation pharmaceutiquement acceptables desdits composés, formule dans laquelle chacun de A, R3-8, X3, X5, m et n répond à la définition figurant dans le présent mémoire. L'invention concerne également des compositions pharmaceutiques contenant les composés de formule (I) et des méthodes pour le traitement de troubles hyperprolifératifs chez un mammifère par administration des composés de formule (I).
TNP2006000200A 2003-12-23 2006-06-22 Derives de quinoleine nouveaux TNSN06200A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53272503P 2003-12-23 2003-12-23
PCT/IB2004/004151 WO2005063739A1 (fr) 2003-12-23 2004-12-13 Derives nouveaux de quinoleine

Publications (1)

Publication Number Publication Date
TNSN06200A1 true TNSN06200A1 (fr) 2007-11-15

Family

ID=34738830

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000200A TNSN06200A1 (fr) 2003-12-23 2006-06-22 Derives de quinoleine nouveaux

Country Status (33)

Country Link
US (2) US7381824B2 (fr)
EP (1) EP1699780A1 (fr)
JP (1) JP4503022B2 (fr)
KR (1) KR100807920B1 (fr)
CN (1) CN1890234A (fr)
AP (1) AP2006003619A0 (fr)
AR (1) AR048292A1 (fr)
AU (1) AU2004309166B2 (fr)
BR (1) BRPI0418102A (fr)
CA (1) CA2551508C (fr)
CR (1) CR8482A (fr)
EA (1) EA009994B1 (fr)
EC (1) ECSP066671A (fr)
GE (1) GEP20084572B (fr)
GT (1) GT200400274A (fr)
HN (1) HN2004000544A (fr)
IL (1) IL175947A (fr)
IS (1) IS8439A (fr)
MA (1) MA28396B1 (fr)
MX (1) MXPA06007242A (fr)
MY (1) MY139446A (fr)
NL (1) NL1027847C2 (fr)
NO (1) NO20063382L (fr)
NZ (1) NZ547009A (fr)
OA (1) OA13349A (fr)
PE (1) PE20050757A1 (fr)
SG (1) SG141459A1 (fr)
TN (1) TNSN06200A1 (fr)
TW (1) TWI331148B (fr)
UA (1) UA82577C2 (fr)
UY (1) UY28692A1 (fr)
WO (1) WO2005063739A1 (fr)
ZA (1) ZA200603657B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
EP1711495A2 (fr) * 2004-01-23 2006-10-18 Amgen Inc. Quinolines, chinazolines, pyridines et pyrimidines et leur utilsation dans le traitement d'inflammation, angiogenèse et le cancer
RU2369607C1 (ru) * 2005-08-08 2009-10-10 Пфайзер Инк. Соли и полиморфные модификации ингибитора vegf-r
CA2632384A1 (fr) * 2005-12-05 2007-06-14 Pfizer Products Inc. Procedes de preparation d'un inhibiteur du vegf-r
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008020302A2 (fr) * 2006-08-17 2008-02-21 Pfizer Products Inc. Composés hétéro-aromatiques à base de quinoline
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
RU2455994C2 (ru) 2007-04-16 2012-07-20 Хатчисон Медифарма Энтерпрайзис Лимитед Пиримидиновые производные
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
RU2011119478A (ru) * 2008-10-14 2012-11-27 Нин Си Соединения и способы применения
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
AU2010229147B2 (en) * 2009-03-21 2012-07-05 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
EP2496578A4 (fr) 2009-11-05 2013-08-21 Univ Notre Dame Du Lac Composés d'imidazo[1,2-a]pyridine, leur synthèse et procédés pour les utiliser
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
FR2973703A1 (fr) * 2011-04-08 2012-10-12 Univ Provence Aix Marseille 1 Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
EP2958911B1 (fr) 2013-02-21 2017-10-18 GlaxoSmithKline Intellectual Property Development Limited Quinazolines en tant qu'inhibiteurs de kinase
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN103524409B (zh) * 2013-09-26 2015-09-02 上海仁力医药科技有限公司 喹啉类化合物及其制备方法与应用
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
EP2974729A1 (fr) * 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
EP3293177A4 (fr) * 2015-04-07 2018-12-12 Guangdong Zhongsheng Pharmaceutical Co., Ltd Inhibiteur de la tyrosine kinase et composition pharmaceutique le comprenant
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
CA2998375A1 (fr) 2015-09-17 2017-03-23 Marvin J. Miller Composes heterocycliques contenant de la benzylamine et compositions utiles contre une infection mycobacterienne
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
EP3521276B1 (fr) 2016-09-30 2021-03-10 Guangdong Raynovent Biotech Co., Ltd. Forme cristalline, forme de sel, et procédé de préparation d'inhibiteur de tyrosine kinase
CN107337634B (zh) * 2017-08-28 2019-07-09 新发药业有限公司 一种阿贝西利中间体化合物的制备方法
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
TW202340164A (zh) * 2022-01-21 2023-10-16 大陸商深圳默元生物科技有限公司 Ｎ－羥基喹啉甲醯胺化合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (fr) 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
JPS62168137A (ja) 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (fr) 1991-05-29 1994-03-16 Pfizer Inc. Composes tricycliques polyhydroxyliques inhibiteurs de la tyrosine-kinase
EP0597003A1 (fr) 1991-08-02 1994-05-18 Pfizer Inc. Derives de quinoline utilises comme immunostimulants------------
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0746554A1 (fr) 1994-02-23 1996-12-11 Pfizer Inc. Derives de la quinazoline a substitution 4-heterocyclyle, procedes d'elaboration et utilisations correspondantes comme agents anticancereux
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (fr) 1994-11-12 1997-12-01 Zeneca Ltd
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1996040142A1 (fr) 1995-06-07 1996-12-19 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
WO1997049688A1 (fr) 1996-06-24 1997-12-31 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
EP0907649A1 (fr) 1996-06-27 1999-04-14 Pfizer Inc. Derives de 2-(2-oxo-ethylidene)-imidazolidin-4-one et leur utilisation comme inhibiteurs de la farnesyl-proteine-transferase
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE300521T1 (de) 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
AU4718997A (en) 1996-11-27 1998-06-22 Pfizer Inc. Fused bicyclic pyrimidine derivatives
ATE345339T1 (de) 1997-02-19 2006-12-15 Berlex Lab N-heterocyclische derivate als nos inhibitoren
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
CA2290021A1 (fr) 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
CA2291709A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
EP1017682A4 (fr) 1997-09-26 2000-11-08 Merck & Co Inc Nouveaux inhibiteurs de l'angiogenese
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
EP1086705A4 (fr) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
EP1082305A4 (fr) 1998-05-29 2001-09-26 Sugen Inc Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
DK1117659T3 (da) * 1998-09-29 2004-03-22 Wyeth Corp Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
PL206627B1 (pl) * 1999-01-22 2010-09-30 Kirin Pharma Kk Pochodna chinazoliny, jej zastosowanie i kompozycja farmaceutyczna
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
DE60018216T2 (de) 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
US7135466B2 (en) 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
AU2001249393A1 (en) 2000-03-22 2001-10-03 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
AU2001249736A1 (en) 2000-03-31 2001-10-15 Cornell Research Foundation, Inc. Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1297016B1 (fr) 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Utilisation d'inhibiteurs du facteur de croissance placentaire pour le traitement de l'angiogenese pathologique, de l'arteriogenese pathologique, de l'inflammation, de la formation tumorale et/ou de la fuite vasculaire
BR0113056A (pt) * 2000-08-09 2003-07-08 Astrazeneca Ab Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
KR100389127B1 (ko) 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
WO2002030453A1 (fr) 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Procedes d'inhibition de l'angiogenese utilisant des inhibiteurs de la nadph-oxydase
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
ATE369894T1 (de) 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
WO2002064170A1 (fr) 2001-02-09 2002-08-22 Children's Medical Center Corporation Methode pour traiter le cancer et augmenter le taux d'hematocrite
US20040241160A1 (en) 2001-07-13 2004-12-02 Yan Wu Vegfr-1 antibodies to treat breast cancer
US7495104B2 (en) 2001-10-17 2009-02-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
PT1441714E (pt) 2001-10-25 2008-03-10 Novartis Ag Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2
EP1483268A2 (fr) * 2002-03-01 2004-12-08 Pfizer Inc. Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
TW200420542A (en) 2002-08-23 2004-10-16 Kirin Brewery A compound having TGF β inhibition activity and a medicinal composition containing the same
EP1522540A4 (fr) 2002-08-30 2011-08-10 Eisai R&D Man Co Ltd Derives d'azaarene
GEP20084572B (en) * 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives

Also Published As

Publication number Publication date
NL1027847A1 (nl) 2005-06-27
UY28692A1 (es) 2005-07-29
AP2006003619A0 (en) 2006-06-30
NL1027847C2 (nl) 2006-04-19
AU2004309166A1 (en) 2005-07-14
UA82577C2 (en) 2008-04-25
US20050137395A1 (en) 2005-06-23
MY139446A (en) 2009-10-30
US7923457B2 (en) 2011-04-12
NZ547009A (en) 2009-09-25
TWI331148B (en) 2010-10-01
IL175947A (en) 2012-08-30
MXPA06007242A (es) 2006-08-18
GT200400274A (es) 2005-09-20
OA13349A (en) 2007-04-13
US7381824B2 (en) 2008-06-03
GEP20084572B (en) 2008-12-25
CR8482A (es) 2007-12-17
JP4503022B2 (ja) 2010-07-14
JP2007516273A (ja) 2007-06-21
PE20050757A1 (es) 2005-10-31
CA2551508A1 (fr) 2005-07-14
AU2004309166B2 (en) 2008-02-21
KR20060101548A (ko) 2006-09-25
ECSP066671A (es) 2006-10-25
MA28396B1 (fr) 2007-01-02
CN1890234A (zh) 2007-01-03
SG141459A1 (en) 2008-04-28
BRPI0418102A (pt) 2007-04-27
NO20063382L (no) 2006-09-20
AR048292A1 (es) 2006-04-19
ZA200603657B (en) 2007-08-29
TW200526218A (en) 2005-08-16
CA2551508C (fr) 2011-08-09
EA200600892A1 (ru) 2006-12-29
KR100807920B1 (ko) 2008-02-27
IL175947A0 (en) 2006-10-05
EA009994B1 (ru) 2008-06-30
EP1699780A1 (fr) 2006-09-13
HN2004000544A (es) 2010-06-09
IS8439A (is) 2006-05-04
US20090069316A1 (en) 2009-03-12
WO2005063739A1 (fr) 2005-07-14

Similar Documents

Publication Publication Date Title
TNSN06200A1 (fr) Derives de quinoleine nouveaux
FR2757157B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA26770A1 (fr) Diarylamines substituees par 1-heterocycle.
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
TNSN06386A1 (fr) Derives de tetraazabenzo [e] azulene et leurs analogues
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN06051A1 (fr) Derives de piperazine pour le traitement d'infections par le hiv
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
TNSN06348A1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
MA28653B1 (fr) Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27661A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
MA27775A1 (fr) Composes organiques
SE0302760D0 (sv) New compounds
SE0201544D0 (sv) Novel compounds and thier use
MA29791B1 (fr) Composes therapeutiques.
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
EP1389616A4 (fr) Nouveaux composes de benzylpiperidine